The Cause of Alzheimer's Might Be Coming From Within Your Mouth
In recent years, an increasing number of scientific investigations have backed an alarming hypothesis: Alzheimer's disease may not be merely a condition of an aging brain, but the product of infection.
While the exact mechanisms of this infection are something researchers are still trying to isolate, numerous studies suggest the deadly spread of Alzheimer's goes way beyond what we used to think.
One such study, published in 2019, suggested what could be one of the most definitive leads yet for a bacterial culprit behind Alzheimer's, and it comes from a somewhat unexpected quarter: gum disease.
Watch the video below for a summary of their study:
In a paper led by senior author Jan Potempa, a microbiologist from the University of Louisville, researchers reported the discovery of Porphyromonas gingivalis – the pathogen behind chronic periodontitis (aka gum disease) – in the brains of deceased Alzheimer's patients.
It wasn't the first time the two factors have been linked, but the researchers went further.
In separate experiments with mice, oral infection with the pathogen led to brain colonization by the bacteria, together with increased production of amyloid beta (Aβ), the sticky proteins commonly associated with Alzheimer's.
The research team, coordinated by pharma startup Cortexyme, which was co-founded by first author Stephen Dominy, wasn't claiming to have discovered definitive evidence of Alzheimer's causation.
But it was clear they thought we had a strong line of investigation here.
P. gingivalis' gingipains (red) among neurons in the brain of a patient with Alzheimer's. (Cortexyme)
"Infectious agents have been implicated in the development and progression of Alzheimer's disease before, but the evidence of causation hasn't been convincing," Dominy said at the time.
"Now, for the first time, we have solid evidence connecting the intracellular, Gram-negative pathogen, P. gingivalis, and Alzheimer's pathogenesis."
In addition, the team identified toxic enzymes called gingipains secreted by the bacteria in the brains of Alzheimer's patients, which correlated with two separate markers of the disease: the tau protein, and a protein tag called ubiquitin.
But even more compellingly, the team identified these toxic gingipains in the brains of deceased people who were never diagnosed with Alzheimer's.
That's important, because while P. gingivalis and the disease have been linked before, it's never been known – to put it simply – whether gum disease causes Alzheimers, or whether dementia leads to poor oral care.
The fact that low levels of gingipains were evident even in people who were never diagnosed with Alzheimer's could be a smoking gun – suggesting they might have developed the condition if they had lived longer.
"Our identification of gingipain antigens in the brains of individuals with AD and also with AD pathology but no diagnosis of dementia argues that brain infection with P. gingivalis is not a result of poor dental care following the onset of dementia or a consequence of late-stage disease, but is an early event that can explain the pathology found in middle-aged individuals before cognitive decline," the authors explained in their paper.
Further, a compound formulated by the company called COR388, showed in experiments with mice that it could reduce bacterial load of an established P. gingivalis brain infection, while also reducing amyloid-beta production and neuroinflammation.
We'll have to wait and see what future research will uncover about this link, but the research community is cautiously optimistic.
"Drugs targeting the bacteria's toxic proteins have so far only shown benefit in mice, yet with no new dementia treatments in over 15 years it's important that we test as many approaches as possible to tackle diseases like Alzheimer's," chief scientific officer David Reynolds from Alzheimer's Research commented in a statement.
The findings were reported in Science Advances.
An earlier version of this story was published in January 2019.
Common Diabetes Drug Linked to 'Exceptional Longevity' in Women
Increased Toxicity Risk Identified For Children With ADHD, Autism
Coffee Could Be The Secret to Healthy Aging For Women, Scientists Discover
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
UCSD students protest Trump cuts to science research funding
SAN DIEGO (FOX 5/KUSI) — For the second time this year, students and faculty at the University of California, San Diego (UCSD) staged a protest outside Geisel Library, demanding the federal government reverse deep education funding cuts imposed by the Trump administration — cuts they say are threatening research, jobs and the future of scientific innovation. Dozens of protesters gathered on campus, holding signs and sharing personal stories about how the loss of federal research grants is impacting their work and well-being. Dozens possibly detained by federal officials amid immigration raids in Los Angeles 'This year has been filled with many moments of insecurity,' said Eleanor Ketterer-Sykes, a first-year Ph.D. student in the neuroscience program. 'UCSD is one of the best science schools in the country because of its renowned research labs, you have access to labs at the Salk Institute, Sanford and Scripps as well as the VA Hospital — but that future is in jeopardy.' The Trump administration has canceled hundreds of research grants in recent months, citing concerns over 'ideologically driven science.' The cuts have targeted studies ranging from HIV prevention to violence prevention in children. UCSD Chancellor Pradeep Khosla warned in an April letter that the university stands to lose between $75 million and $500 million annually as a result. 'As of May 30, there have been more than 150 federal grants terminated, resulting in a loss of $30 million,' said Lisa Eyler, a UCSD psychiatry professor. 'These cuts are already leading to layoffs among instructors, staff scientists, and support personnel like librarians.' 'No Kings Day' protests planned across California on June 14 The ripple effects could be felt beyond UCSD. Stanley Maloy, emeritus professor of microbiology at San Diego State University, said the cuts threaten the pipeline of future scientists and engineers. 'Reduced positions mean talented students are left behind,' Maloy said. 'As this innovation workforce dries up, our economy is going to suffer.' Eyler echoed those concerns, warning of a generational loss in scientific progress. 'There will be a gaping hole in the pipeline of future scientists, engineers and healthcare providers, which could result in the potential loss of an entire generation of great scientific thinkers,' she said. Thousands in San Diego protest cuts to federal education funds For Ketterer-Sykes, the issue is personal. She entered the neuroscience program hoping to make life-saving breakthroughs. 'So many people rely on scientific innovation — whether it be to find cures for diseases like tuberculosis or Alzheimer's disease,' she said. 'It really is vital to humanity.' While the exact financial toll remains uncertain, university leaders say the impact is already being felt — and may only get worse. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
5 hours ago
- Yahoo
Tips to take care of your brain for Alzheimer's and Brain Health Awareness Month
June is Alzheimer's and Brain Health Awareness Month and people hoping to spread that awareness said there are things you can do to take charge of your brain health. Brain changes that cause Alzheimer's can begin 20 years or more before symptoms appear. Work to start on Rockdale Road next week Doing things like exercising, eating right, getting good quality sleep, and controlling blood pressure can improve brain health and reduce the risk of cognitive decline. While age and family history are factors, these can naturally help you to reduce your risk. Millcreek man says over $1000 was stolen from EBT account 'It's not just the individual with the diagnosis, but it's the over 480 thousand caregivers here in the state of Pennsylvania that are providing that care. It's the family members that are in that circle of care who need that information and support. We want people to know they're not alone,' said Sara Murphy, vice president of programs and services for the Alzheimer's Association Greater PA Chapter. Early detection of cognitive diseases is crucial. The Alzheimer's Association also has a help line that anyone can call to get support at 1-800-272-3900. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
8 hours ago
- Yahoo
Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory
We came across a bullish thesis on Alpha Cognition Inc. Common Stock (ACOG) by anygal on r/investing on Reddit. In this article, we will summarize the bulls' thesis on ACOG. Alpha Cognition Inc. Common Stock (ACOG)'s share was trading at $9.33 as of 30th May. ACOG's forward P/E was 26.88 according to Yahoo Finance. A chemist in a laboratory analyzing data from the various therapeutic tests conducted. Alpha Cognition Inc. (NASDAQ: ACOG) represents a potentially overlooked opportunity in the Alzheimer's treatment space, having recently launched its oral drug, Zunveyl, at the end of March. With a current market cap of $150 million and $45 million in cash, the company is targeting the underserved segment of the Alzheimer's population—specifically, the 50% of patients in long-term care (LTC) not taking any current medications due to severe side effects. Unlike other galantamine-based drugs, Zunveyl significantly slows disease progression and improves short-term memory with a markedly better safety profile—only one serious side-effect case was reported in its Phase 3 trials, versus a 50% rate seen in traditional options. The drug's Medicare coverage further eases affordability, lowering monthly out-of-pocket costs to $30–$190. Initial demand appears promising, with nearly 500 patients starting treatment in the first two weeks of launch. Even a modest 1% market penetration into the LTC segment could yield $135 million in annual revenue, with $67.5 million in net income assuming 50% margins. A 5% penetration would put net income at $675 million, dwarfing the current valuation. Alpha Cognition has also secured a distribution deal with a major Chinese pharmaceutical firm, creating a royalty-based revenue stream in Asia. While the upside is substantial, key risks remain—most notably, the emergence of unforeseen serious side effects post-launch, which could lead to FDA scrutiny or suspension of sales. Still, the market's underreaction and the company's positioning as a safer, effective alternative in a high-need space make ACOG a high-upside, high-conviction bet for risk-tolerant investors. Previously, we have covered ACOG in March 2025 wherein we summarized a by BullishDoctor on Twitter. The user highlighted that Alpha Cognition Inc.'s drug ZUNVEYL addressed the major side effects of existing Alzheimer's treatments, making it highly tolerable and poised for adoption in long-term care facilities, a $2 billion market. The company was pre-revenue but launched in March 2025 with strong physician support, a nearly complete sales force, and promising catalysts like a Phase 4 study and sublingual formulation, projecting breakeven within three years. Since our last coverage, the stock is up 61% as of 30th May. Alpha Cognition Inc. Common Stock (ACOG) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 8 hedge fund portfolios held ACOG at the end of the first quarter which was 10 in the previous quarter. While we acknowledge the potential of ACOG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data